scholarly journals Not all cardiac glycosides are equal: Could ouabain prove to be better than digoxin for heart failure?

2015 ◽  
Vol 24 ◽  
pp. S213
Author(s):  
A. Garcia ◽  
C. Liu ◽  
W. Hannam ◽  
N. Fry ◽  
H. Rasmussen
2015 ◽  
Vol 34 (2) ◽  
pp. 95-102 ◽  
Author(s):  
Francisca Caetano ◽  
Paula Mota ◽  
Inês Almeida ◽  
Andreia Fernandes ◽  
Ana Botelho ◽  
...  

2018 ◽  
Vol 28 (10) ◽  
pp. 106312 ◽  
Author(s):  
Philine Granitza ◽  
Jan F. Kraemer ◽  
Christoph Schoebel ◽  
Thomas Penzel ◽  
Jürgen Kurths ◽  
...  

1984 ◽  
Vol 22 (2) ◽  
pp. 7-8

Similar oral preparations of isosorbide mononitrate have recently been marketed by four unrelated companies. This is unusual but understandable for an unpatentable drug of promise. Like other nitrates this drug has anti-anginal and haemodynamic effects of value in the treatment of ischaemic heart disease and heart failure. The manufacturers claim that its 100% bioavailability should make it more effective, longer acting and more acceptable than slow-release isosorbide dinitrate (ISDN).


2011 ◽  
Vol 56 (4) ◽  
pp. 1-3 ◽  
Author(s):  
M Haden ◽  
D A S Marshall ◽  
B Murphy

We report a previously healthy man presenting with life-threatening hyperkalaemia and heart failure. The only possible cause was thought to be the long list of herbal medications he was taking, several of which contained significant amounts of cardiac glycosides. Hyperkalaemia is known to be associated with digoxin toxicity and we present this as the likely cause in this case, and emphasize the importance of a thorough drug history in forming a differential diagnosis.


BMJ ◽  
1999 ◽  
Vol 318 (7197) ◽  
pp. 1509-1509
Author(s):  
S. Gottlieb
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document